Primary lung cancer
Conditions
Interventions
The landiolol hydrochloride of 0.005mg/kg/min is administered to a patient through a indwelling aortic catheter from commencing surgery to postoperative day1 with adjusting the landiolol hydrochloride
Sponsors
Department of Thoracic Surgery, Kitasato University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Including primary lung cancer patients who meet any one following conditions, a cardiac disease, bilobectomy with thoracotomy, lung resection with a bronchial formation or angiogenesis, lung resection with composite resection of organ around lung.
Exclusion criteria
Exclusion criteria: Patient corresponding to the contraindication of landiolol hydrochloride 1) Patients with cardiogenic shock 2) Patients with diabetic ketoacidosis or metabolic acidosis 3) Patients with auriculoventricular block(out of 2nd degree) or bradyarrhythmia including sick sinus syndrome 4)Patients with right cardiac failure from pulmonary hypertension 5) Patients with congestive cardiac failure 6) Patients with untreated phaeochromocytoma 7) Patients with a previous history of hypersensitivity to components of landiolol hydrochloride 8) Patients with bronchial asthma 9) Patient with sick sinus syndrome(Including a pacemaker implantation) 10) Patient who is pregnant woman also possibility of pregnancy or nursing mother 11) Patient who is judged as inappropriate by doctor in attendance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the tachyarrhythmia incidence up to postoperative 72 hours between landiolol hydrochloride administration group and the non-administration group | — |
Countries
Japan
Contacts
Public ContactYukitoshi Satoh
Kitasato University School of Medicine Department of Thoracic Surgery
Outcome results
None listed